Epoxide hydrolase inhibition and Thiazolidinediones: A therapy for cardiometabolic syndrome

(Society for Experimental Biology and Medicine) Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock determined the synergistic actions of inhibiting soluble epoxide hydrolase with tAUCB and activating peroxisome proliferator-activator receptorγ with the thiazolidinedione rosiglitazone on the pathological progression of cardiometabolic syndrome. Cardiometabolic syndrome occurs with obesity and hypertension increasing risks for cardiovascular disease and causing significant, rapidly progressive kidney disease.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news